Isabelle Bekeredjian-Ding elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI)
On 9 November 2018, the IMI Scientific Committee elected Professor Isabelle Bekeredjian-Ding, head of Division Microbiology at the Paul-Ehrlich-Institut (PEI) as its chair for a period of two years. The primary purpose of IMI is to provide access to innovative medicines for people in Europe, including the increasing number of elderly people, and to support the development of such medicines. Its focus is on advanced vaccines and antibiotics during the tendering phase of IMI2 (2014 – 2020).
"The Paul-Ehrlich-Institut is committed to biomedicine in international organisations at the highest scientific level. The election of Professor Bekeredjian-Ding as chair of the Scientific Committee of IMI is a special recognition both for her personally and for the PEI. I am very pleased that we are able to shape the future of medicines development and supplies actively in Europe that way," said Professor Klaus Cichutek, president of the PEI.
IMI is a joint initiative of the European Union (EU), represented by the European Commission and the (bio)pharmaceutical industry (European Federation of Pharmaceutical Industries Associations, EFPIA). The major players of health research form an organisation for the purpose of working on their joint projects. This organisation includes universities, research centres, pharmaceutical manufacturers, patient advocacy organisations, and regulatory medicines authorities.